We’re attending the GenScript Biotech Global Forum 2024 event in London where Reagan Jarvis will present expert insights into our innovative approach in cell therapy. Reagan joins Stephen Hansen (BioCentury Inc.) Pascal Touchon (Atara Biotherapeutics), Biao Zheng (BRL Medicine 邦耀生物), Ying Huang (Legend Biotech) and Jason C. Foster (Ori Biotech) to discuss recent advancements in cell therapy, and how we are contributing with our unique approach that replicates T-cell biology in the lab to identify disease targets and build T-cell immunotherapies. Mark Farmery and Jacob Michlewicz will also be in attendance, don’t miss the opportunity to connect with them there. 🔗Join #GenScript2024: https://lnkd.in/erzpMHkT #Biotech #Pharma #CellTherapy #Oncology #TCR
Om oss
Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity. Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.
- Webbplats
-
http://www.anocca.com
Extern länk för Anocca
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 51–200 anställda
- Huvudkontor
- Södertälje
- Typ
- Privatägt företag
- Grundat
- 2014
- Specialistområden
- Biotechnology, Immunotherapeutics, Drug Discovery, Drug Development, Immunology, Immunotechnology och Immuno-Oncology
Adresser
-
Primär
Forskargatan 20C
B229
Södertälje, 15136, SE
Anställda på Anocca
Uppdateringar
-
We’re looking forward to participating at the LSX Inv€$tival Showcase 2024, November 18 in London! Meet Jacob Michlewicz, and join Reagan Jarvis as he showcases how our proprietary technology platform is targeting the hardest to treat solid tumours. Later that evening, Reagan and Jacob will be joined by Mark Farmery and Dan Kemp from Shinobi Therapeutics at the LSX European Lifestars Awards 2024 to celebrate a significant milestone - our strategic partnership with Shinobi has been shortlisted as a finalist for Deal of the Year (up to €500m)! Together, we are pioneering new pathways to develop allogeneic TCR-T cell therapies for solid tumours. We are happy to be listed among an esteemed group of finalists LAVA Therapeutics N.V. & MSD, EraCal Therapeutics & Novo Nordisk, Autolus Therapeutics & BioNTech SE, Biolojic Design, Ltd. & Merck Group. 🔗 Join #LSXInvestival: https://lnkd.in/eP7Cz4CS Informa Connect LSX - partnering for Life Science eXecutives #Biotech #Pharma #LSXInvestival #TCR #Immunotherapy #CellTherapy
-
We’re set to join industry leaders in Stockholm at BIO-Europe 2024 from November 4-6, where we’ll be discussing the transformative potential of TCR-T cell therapies as event sponsors and as part of the Swedish Pavillion. Meet us there: 🤝 https://lnkd.in/dRGyPtmn Reagan Jarvis joins a high-profile panel together with Romain Bonnot, Pharm.D (ZS), Celine Carlet (Galapagos), Michael May (CCRM), Bernd Muehlenweg (Evotec) and Dan Kemp from our strategic partners Shinobi Therapeutics. They will explore how cell and gene therapy can reshape healthcare, focusing on advances in therapeutic applications, disease treatment, and prevention. Mark Farmery, Jacob Michlewicz and Zach Chia will also be in attendance, ready to discuss the progress of our KRAS program and our upcoming transition to a clinical stage company, along with the development of our pipeline and opportunities for investment, collaboration and partnership. 🤝 Schedule a meeting with us: https://lnkd.in/dRGyPtmn 🔗 #BIOEurope2024: https://lnkd.in/dnuNZ2D #Biotech #Pharma #Innovation #CellTherapy #CancerResearch #TCR #JoinSwedishLifeScience #InnovationforLife Informa Connect Life Sciences
-
Join us at the European Society of Gene and Cell Therapy annual congress in Rome from October 22-25, where our CTO Luke Pase will present a poster on Anocca’s clinical TCR candidate library development. 📅 October 24 | 14:00–15:30 | Poster Session 3 | P0771 Establishing a clinical TCR candidate library through systematic and scalable cell-based platform Learn how our platform discovers peptide-HLA (pHLA) targets and therapeutic TCRs at a scale to enable TCR-T library deployment for personalised therapy. Our lead TCR-T product, targeting shared KRAS tumour antigens, is progressing to clinical trials, marking the first step in a broader program aimed at hard-to-treat solid tumours. 🔗 Join us at ESGCT Congress 2024: https://lnkd.in/efye-f8c #Biotech #Pharma #CellTherapy #Oncology #TCRT #ESGCT2024
-
Mark Farmery led a workshop at Nordic Life Science Days 2024 in Malmo exploring innovation, collaboration, and the future of cell & gene therapy in the Nordics. Joined by Elsa Abranches (AstraZeneca), Janet Hoogstraate (NorthX Biologics), and Fredrik Wessberg (CCRM Nordic), the session sparked dynamic discussions on driving CGT forward. Discover how: 🌐The Nordic region is poised to lead innovation in CGT, backed by strong healthcare infrastructure and cutting edge research 🤝Collaboration is critical to reduce production costs and drive productivity in CGT 💡 The Nordic ecosystem plays a key role in attracting and nurturing top talent ⚙️ Standardisation is essential for efficient scaling and production of advanced therapies 🔗Read the full feature to dive into the key takeaways and learn how Anocca is shaping the future of cell & gene therapy: https://lnkd.in/dMH5RA9t #Biotech #Pharma #CellAndGeneTherapy #TCR #Nordics #NLSDays2024 Scius Communications
-
We’re excited to be joining the LSX Nordic Congress in Copenhagen where co-founder and CEO Reagan Jarvis will be participating as an expert speaker. 📅 October 9 | 11.00-11:50 | Nordic Biotech Brilliance: Unleashing the Talent Magnet for Sustained and Retained Innovation This session will explore how the Nordic region can attract and retain top-tier talent to sustain innovation in biotech and pharma. We are advancing to the clinic with our multi-asset mutant KRAS program that has been developed by our proprietary platform technologies and in-house manufacturing capabilities. To learn more, schedule a 1:1 meeting with Reagan: https://lnkd.in/e_bDpN4W 🔗Register for #LSXNordic2024: https://lnkd.in/eCkHc4Rq #Pharma #Biotech #CellTherapy #TCRT LSX - partnering for Life Science eXecutives Mario Alzamora (Nucleate Denmark, Georgina Askeland, PhD (Hadean Ventures), Stine Kruse (DTU Skylab)
-
Meet with our CDO Mark Farmery at the Alliance for Regenerative Medicine’s 2024 Cell and Gene Meeting on the Mesa in Phoenix from October 7-9, and join our company presentation. 👉 https://lnkd.in/edKBRYf 📅 8 October | 11:30-11:45 | FLW Ballroom G Mark will share an update on recent progress across the company, including our multi-asset TCR-T program targeting KRAS driver mutations, which is advancing into clinical development. 🔗Event info: https://lnkd.in/eiUpMy4 🤝Schedule a meeting with Mark: https://lnkd.in/edKBRYf #biotech #pharma #celltherapy #innovation #TCR
-
Our CFO, Jacob Michlewicz was delighted to share our perspectives on #biotech funding and #finance at the recently concluded Nordic Life Science Days. Read about it below. #investmentstrategy #lifescience
💬 –"You might brag about raising $100m in Boston to fund all the things you could do there, but in Sweden, Denmark, Norway, Iceland, and Finland, they’d likely only need $10m to achieve all that and still have a chunk of change left too." 💡 One of the standout super sessions at this year's NLSDays focused on funding and finance 💶 featuring Inka Mero from Voima Ventures, Laurentz Govaertz from EQT Life Sciences, Jacob Michlewicz from Anocca, Jonathan P. Gertler, MD from Back Bay Life Science Advisors and Diana Röttger, PhD from APEX Ventures. Daniel Gooch from Scius Communications was there to break down the discussions and share key insights. Check it out below ⬇️
NLSDays Panel - Money, Money, Money: How to attract more international investors to the Nordics - NLSDays
https://www.nlsdays.com
-
Our CFO Jacob Michlewicz and CDO Mark Farmery had a very fruitful Nordic Life Science Days last week with great discussions throughout the event. We would like to say thank you to our fellow panellists and the organisers, SwedenBIO! Thank you to Inka Mero(Voima Ventures), Laurenz Govaerts (EQT Life Sciences), Jonathan P. Gertler, MD (Back Bay Life Science Advisors), and Diana Röttger, PhD (APEX Ventures), for the enlightening panel discussion with Jacob on attracting more international investors to the Nordics Thank you also to Elsa Abranches (AstraZeneca), Janet Hoogstraate (NorthX Biologics), and Fredrik Wessberg (CCRM Nordic), for a fantastic workshop together with Mark to explore the Nordic opportunity in CGT
-
Thank you Brad Loncar and BiotechTV for meeting with Reagan Jarvis, our CEO, at Anocca HQ to discuss how we are tackling key cancer drivers such as KRAS and p53 with our precise, scalable, and differentiated approach to mapping disease targets and developing therapeutic TCRs 👇
𝐅𝐫𝐨𝐦 𝐒𝐭𝐨𝐜𝐤𝐡𝐨𝐥𝐦: Anocca is a TCR-T company with a unique approach that is going after unique targets, its first CTA will be filed soon. Co-Founder and CEO Reagan Jarvis describes Anocca's TCR mapping, discovery, and engineering approach, as well as why they have chosen targets such as KRAS and P53. Full video: https://lnkd.in/gJq-AmS9 BiotechTV's coverage of Sweden area biotech companies is brought to you by: Pareto Securities
Liknande sidor
Finansiering
Senaste finansieringsrunda
Okänd serie36 891 357,00 US$